IMPROVE-IT provided randomized evidence that adding ezetimibe to statin therapy after acute coronary syndrome can further reduce cardiovascular events. More than 18,000 patients were randomized to simvastatin plus ezetimibe or simvastatin alone and followed for several years. The combination produced a modest but statistically significant reduction in the primary composite cardiovascular endpoint, accompanied by greater LDL-cholesterol lowering. For general physicians, the study reinforces the principle that cumulative LDL exposure matters and that treatment escalation can be justified when statin therapy alone does not achieve the desired lipid reduction. The trial also helped establish ezetimibe as a practical first add-on therapy because of its oral administration, tolerability and evidence base. In patients with atherosclerotic cardiovascular disease, lipid management should therefore move beyond “statin yes/no” and toward assessment of achieved LDL-C, treatment adherence, secondary causes and the need for additional therapy. The clinical challenge remains implementation: patients often receive lower-than-needed doses, discontinue therapy or are not rechecked after initiation. A structured lipid pathway can convert strong trial evidence into more consistent risk reduction.